This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ENTL (ENTL) (ENTL) Stock Price, News & Analysis Add Share Share Stock Analysis Stock AnalysisBuy This Stock About (ENTL) Stock (NASDAQ:ENTL) Get (ENTL) alerts:Sign Up Key Stats Today's Range$24.00▼$24.0050-Day Range$24.00▼$24.0652-Week Range$11.47▼$25.58VolumeN/AAverage Volume178,331 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Entellus Medical, Inc. is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment. The Company's XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The MiniFESS family of surgical instruments includes eight devices designed to enable physicians to perform various surgical procedures. The Fiagon Image Guidance System (IGS) consists of a navigation unit, navigation sensor, software instruments and a patient localizer. Read More Receive ENTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (ENTL) and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENTL Stock News HeadlinesNottingham Forest entlässt Trainer Espirito SantoSeptember 9, 2025 | msn.comEuropa-League-Gegner von Sturm entlässt TrainerSeptember 9, 2025 | msn.comCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.October 2 at 2:00 AM | Timothy Sykes (Ad)Nottingham entlässt Espirito Santo - Postecoglou KandidatSeptember 9, 2025 | de.nachrichten.yahoo.comNestle entlässt Konzernchef Freixe - Nespresso-Leiter Navratil übernimmtSeptember 1, 2025 | de.finance.yahoo.comBeziehung zu Mitarbeiterin: Nestlé entlässt KonzernchefSeptember 1, 2025 | de.finance.yahoo.comUS-Außenministerium entlässt 1.300 MitarbeiterJuly 13, 2025 | msn.comUS-Justiz entlässt neun weitere Trump-ErmittlerJuly 13, 2025 | msn.comSee More Headlines ENTL Stock Analysis - Frequently Asked Questions How were (ENTL)'s earnings last quarter? (ENTL) (NASDAQ:ENTL) issued its quarterly earnings data on Thursday, November, 3rd. The medical technology company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by $0.13. (ENTL)'s quarterly revenue was up 20.9% compared to the same quarter last year. When did (ENTL) IPO? (ENTL) (ENTL) raised $70 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Piper Jaffray acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. What other stocks do shareholders of (ENTL) own? Based on aggregate information from My MarketBeat watchlists, some other companies that (ENTL) investors own include Intersect ENT (XENT), Bristol Myers Squibb (BMY), (RLYP) (RLYP), Twitter (TWTR), Altisource Asset Management (AAMC), ACADIA Pharmaceuticals (ACAD) and AcelRx Pharmaceuticals (ACRX). Company Calendar Last Earnings11/03/2016Today10/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:ENTL CIK1374128 Webwww.entellusmedical.com Phone+1-763-4631595FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ENTL) was last updated on 10/2/2025 by MarketBeat.com Staff From Our PartnersClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredFree: The Crypto Summit That Could Change Your LifeFed cuts unleash crypto's next wave The smart money is already moving. This is your chance to see their car...Crypto 101 Media | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredChina’s message to TrumpPorter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (ENTL) Please log in to your account or sign up in order to add this asset to your watchlist. Share (ENTL) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.